MYCN and neuroblastoma: As the tumor niche represents an important biological variable [20,33,34], here we report an immune-competent Th-MYCN-based mouse model that could provide a platform for the in-depth evaluation of localized anti-NB therapeutic activity, including the contribution of diversified immune responses generated downstream of drug, monoclonal antibody, or adoptive cell transfer interventions.